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GLOSSARY
3D = 3 dimensional; ACT = activated clotting time; CI = cardiac index; ECMO = extracorporeal 
membrane oxygenation; Fio2 = fraction of inspired oxygen; ICU = intensive care unit; LV = left 
ventricle; LVEF = left ventricular ejection fraction; MAP = mean arterial pressure; mPAP = mean 
pulmonary arterial pressure; Pao2 = partial pressure of arterial oxygen; PCRTO = pump-controlled 
retrograde trial off; PEEP = positive end-expiratory pressure; ROTEM = rotational thromboelastom-
etry; RV = right ventricle; RVEF = right ventricular ejection fraction; Sao2 = arterial oxygen satura-
tion; Svo2 = mixed venous oxygen saturation; TDSa = tissue Doppler lateral mitral annulus peak 
systolic velocity; TEE = transesophageal echocardiography; TTE = transthoracic echocardiography; 
UFH = unfractionated heparin; vaECMO = venoarterial extracorporeal membrane oxygenation; VTI 
= velocity time integral; vvECMO = venovenous extracorporeal membrane oxygenation
Venoarterial extracorporeal membrane oxygenation (vaECMO) is a well-established treatment for severe cardiogenic shock of various etiologies1 and is indi-
cated as a bridge-to-recovery or a bridge-to-bridge concept 
until a definitive treatment strategy can be defined.2
Depending on the etiology of heart failure, the duration of 
vaECMO support varies from days to weeks.1 When parame-
ters indicating cardiac and pulmonary recovery are reached, a 
weaning attempt is made. Successful weaning from vaECMO 
is defined as removal of the device without further require-
ment for mechanical circulatory support over the next 30 days 
due to refractory (or recurrent) cardiogenic shock.3
Likely due to patients’ heterogeneity and the variation 
in experience, reported success rates for weaning vary 
between 24% and 69%, with in-hospital mortality rates as 
high as 65%.4 The lack of a standardized accepted wean-
ing protocol might further impact weaning success. A brief 
and conclusive checklist is currently lacking. After having 
summarized current guidelines of the Extracorporeal Life 
Support Organization and all PubMed results for the search 
“vaECMO AND weaning,” we developed at our center 
(>100 vaECMOs per year) the evidence-based weaning pro-
tocol describe below.
PREWEANING
General Considerations
vaECMO flow of 50–70 mL/kg/min (4–6 L/min) with gas 
exchange is usually sufficient to support end-organ recovery. 
Extracorporeal membrane gas exchange is typically mandatory 
in classic vaECMO to avoid a high-output-like venoarterial 
fistula-like functional bypass with potentially severe arte-
rial desaturation in settings without gas exchange. Protective 
mechanical ventilation is mandatory in patients with vaECMO 
and includes low tidal volumes of 3–5 mL/kg, ventilation rates 
<8/min, positive end-expiratory pressure (PEEP) <8 cm H2O, 
and fraction of inspired oxygen (Fio2) <0.40.1
Flow reduction is performed every 12–24 hours, aiming at 
the lowest flows that provide adequate support with minimal 
vasoactive agents. This stepdown strategy is to be stopped 
when mean arterial pressure (MAP) falls to <60 mm Hg. 
Echocardiographic evaluation is performed every 24 hours, 
preferably with transesophageal echocardiography (TEE).1,4,5 
Reduction of “ECMO flow to a minimum” and “pump-con-
trolled retrograde trial off” are 2 possible stepdown strate-
gies (Supplemental Digital Content, Table, http://links.lww.
com/AACR/A304) in the preweaning phase.
Myocardial recovery, stable hemodynamics, and suf-
ficient pulmonary function must be present4 to consider 
vaECMO weaning after 72 hours of support4 (earlier in 
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cases of intoxications).5 Therefore, continuous monitoring 
of peripheral (preferably in the right arm) and pulmonary 
artery pressures is recommended.1,6 Lactate concentrations 
are measured regularly to monitor end-organ perfusion and 
metabolism,7 and routine platelet counts >80,000/µL must 
be targeted. A recent survey revealed large global prac-
tice variations in anticoagulation management in ECMO 
patients.8 We use unfractionated heparin (UFH) aiming at 
activated clotting time (ACT) >180 seconds.6
Parameters Predicting Successful  
Weaning From ECMO
Hemodynamics are considered stable with a MAP >60 mm 
Hg and pulsatile arterial waveforms (aortic valve opening) as 
a sign of myocardial recovery1 for ≥24 hours without signifi-
cant vasoactive pharmacological support.4 Increasing pulsa-
tility and pulsatile pressures of >10 mm Hg are associated 
with weaning success,9 and stable hemodynamics contribut-
ing to a physiological homeostasis are reflected in normal 
liver function and normal pH and lactate concentrations.3,4
Normalized lactate concentrations <2.4 mmol/L within 
the first 12 hours of vaECMO support are associated with 
higher rates of weaning success,7 while neither recovery of 
renal function6 nor cardiac biomarkers predict weaning suc-
cess in vaECMO patients.5
While weaning protocols are described mostly using 
transthoracic echocardiography (TTE), hemodynamics are to 
be correlated with left ventricular (LV) and right ventricular 
(RV) function by TTE or TEE10 with minimal ECMO support. 
LV ejection fraction (LVEF) >20%–25%, aortic velocity time 
integral (VTI) >10 cm, tissue Doppler lateral mitral annulus 
peak systolic velocity (TDSa) >6 cm/s, and less than mod-
erate aortic regurgitation are associated with weaning suc-
cess.5 While poor RV function is generally associated with 
decreased weaning success, 3-dimensional (3D) RV ejec-
tion fraction (RVEF) >24.6% predicts weaning success.1,4,5,11 
Measuring RV strain is a reliable alternative in settings 
where 3D technology is not available. If neither 3D RV nor 
strain analysis is available, classical measures of RV function 
are considered. In any case, RVEF is evaluated during reduc-
tion of ECMO flow and during volume administration while 
avoiding systemic hypotension.12 Tricuspid annular plane 
systolic excursion,11 tricuspid regurgitation,11 and indices of 
LV filling pressure3 do not correlate with weaning success.
Vasoactive pharmacological support is kept at the low-
est concentrations possible before weaning initiation. With 
severely reduced LVEF (<25%) or persistent low cardiac out-
put, 0.1 and 0.2 μg/kg/min levosimendan administered 24 
hours before weaning initiation may increase weaning suc-
cess, reduce need of inotropic support after weaning, and 
decrease in-hospital mortality,13 but current evidence is not 
sufficient to unrestrictedly justify the high costs. Milrinone 
at 0.1 and 0.75 µg/kg/min13 appears to be a feasible alterna-
tive.14 Nitric oxide at 20 ppm may be beneficial if there is 
impaired RV function or pulmonary hypertension.14
Figure 1. vaECMO preweaning checklist in the intensive care unit. 3D indicates 3 dimensional; ACT, activated clotting time; CI, cardiac index; 
ECMO, extracorporeal membrane oxygenation; Fio2, fraction of inspired oxygen; ICU, intensive care unit; LV, left ventricle; LVEF, left ventricular 
ejection fraction; MAP, mean arterial pressure; mPAP, mean pulmonary arterial pressure; Pao2, partial oxygen pressure of arterial oxygen; 
PEEP, positive end-expiratory pressure; RV, right ventricle; RVEF, right ventricular ejection fraction; Sao2, arterial oxygen saturation; Svo2, mixed 
venous oxygen saturation; TDSa, tissue Doppler lateral mitral annulus peak systolic velocity; TEE, transesophageal echocardiography; UFH, 
unfractionated heparin; vaECMO, venoarterial extracorporeal membrane oxygenation; VTI, velocity time integral; vvECMO, venovenous extra-
corporeal membrane oxygenation.
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Although protective ventilation aims at avoiding pulmo-
nary complications, some patients may develop pulmonary 
failure, especially after prolonged vaECMO support. In 
cases of respiratory failure, and if the ratio of partial pres-
sure of arterial oxygen (Pao2)/Fio2 is <100 mm Hg with 
ECMO gas flow set at 21%, a stepdown approach using 
venovenous ECMO is an option. Figure  1 displays our 
vaECMO preweaning checklist based on current evidence 
and our experience.
WEANING AND DISCONTINUATION TRIALS
Actual weaning with discontinuation takes place in the 
operating room with the patient under total intravenous 
anesthesia. The American College of Cardiology proposes a 
graduated decrease in flow at the rate of 1 L/h, over a period 
of 3–4 hours.1 Mixed venous oxygen saturation (Svo2) and 
arterial oxygen saturation (Sao2) are maintained at >65% and 
>90%, respectively, at an ECMO flow rate of <1.5 L/min.1 
Native heart or lung function is typically adequate to discon-
tinue vaECMO when support is <25% of total cardiac output.
Vasoactive agents are limited to low doses of norepi-
nephrine, and if necessary, low doses of epinephrine or 
dobutamine.4 Anticoagulation therapy with UFH is con-
tinued, aiming at ACTs >180 seconds postweaning to 
avoid deep vein thrombosis.15 Platelets are maintained 
at >80,000/µL, and regular whole blood viscoelastic 
point-of-care testing includes thromboelastography or rota-
tional thromboelastometry.6,12
During weaning, vasoactive pharmacological agents 
and volume administration are continuously adjusted 
according to hemodynamics. At idle ECMO flow, the MAP 
must be stable at >50 mm Hg, with arterial wave ampli-
tudes >10 mm Hg, cardiac index (CI) >2.4 L/min/m2, 
Svo2 >60%, Sao2 >90%, Pao2 >100 mm Hg, and lactate <2.4 
mmol/L. LVEF must be >20%–25%, aortic VTI >10 cm, and 
TDSa >6 cm/s.1,4 There must be no worsening of biventric-
ular dilation and less than moderate aortic regurgitation.1,4 
RV preload and right heart function cannot be sufficiently 
tested at idle flow.
Discontinuation trials are performed during the weaning 
process to either stop or significantly reduce ECMO circula-
tion and to assess cardiac function before decannulation. The 
Supplemental Digital Content, Table, http://links.lww.com/
AACR/A304, provides an overview of strategies commonly 
used in discontinuation trials. The selected strategy is defined 
before the start of the weaning process.
Before the weaning or discontinuation trial begins, the 
patient is placed on full ventilator support and low-dose 
inotropes are started as needed. Hemodynamic, echocar-
diographic, metabolic, and gas exchange parameters are 
assessed regularly. If they are satisfactory, decannulation is 
performed and protamine is administered. Figure 2 displays 
Figure 2. vaECMO weaning checklist in the operating room. ACT indicates activated clotting time; CI, cardiac index; ECMO, extracorporeal 
membrane oxygenation; Fio2, fraction of inspired oxygen; ICU, intensive care unit; LV, left ventricle; LVEF, left ventricular ejection fraction; 
MAP, mean arterial pressure; Pao2, partial oxygen pressure of arterial oxygen; PCRTO, pump-controlled retrograde trial off; PEEP, positive end-
expiratory pressure; ROTEM, rotational thromboelastometry; RV, right ventricle; RVEF, right ventricular ejection fraction; Sao2, arterial oxygen 
saturation; Svo2, mixed venous oxygen saturation; TDSa, tissue Doppler lateral mitral annulus peak systolic velocity; UFH, unfractionated 
heparin; vaECMO, venoarterial extracorporeal membrane oxygenation; VTI, velocity time integral.
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our vaECMO weaning checklist based on current evidence 
and our experience.
WEANING FAILURE
If hemodynamic, respiratory, and metabolic parameters 
differ from minimum requirements at any stage, weaning 
attempts are stopped and vaECMO support reestablished. 
Weaning must be aborted and ECMO returned to full flow 
if the pharmacological vasoactive support is high, LVEF 
remains <20%–25%, pulsed pressure amplitude is <10 mm 
Hg, or MAP <50 mm Hg is present. Furthermore, wean-
ing must be aborted when CI remains <2.2–2.4 L/min/m2, 
Svo2 <50% or Sao2 <90%, at a PEEP of >12 cm H2O, and 
Fio2 >0.5 or when lactate concentrations are >2.4 mmol/L. 
The patient’s physiology is optimized, and a future wean-
ing attempt is planned for a minimum of 24–48 hours at the 
earliest. The Table summarizes reasons to abort the weaning 
attempt.
CONCLUSIONS
Weaning from vaECMO is a multistage procedure that 
requires careful planning. Continuous assessment of hemo-
dynamic, respiratory, and metabolic parameters is required. 
We recommend development of an institutional checklist. 
Our version is based on current evidence and, while not 
validated, may serve as a guide for successful weaning from 
vaECMO. E
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Table. Hemodynamic and Metabolic Conditions 
Warranting Stopping a Weaning Attempt
Maximal vasoactive support without possibilities of further increase
LVEF <20%–25%
CI < 2.4 L/min/m2
MAP <50 mm Hg
Pulse pressure amplitude <10 mm Hg
Svo2 <50%
Sao2 <90 %
Lactate >2.4 mmol/L
PEEP >12 cm H2O
Fio2 >0.5
Abbreviations: CI, cardiac index; Fio2, fraction of inspired oxygen; LVEF, left 
ventricular ejection fraction; MAP, mean arterial pressure; PEEP, positive end-
expiratory pressure; Sao2, arterial oxygen saturation; Svo2, mixed venous 
oxygen saturation.
